

Accepted Manuscript

Title: Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform

Author: Christopher G. Kanakry, Leo Luznik

PII: S1083-8791(18)30184-8

DOI: <https://doi.org/10.1016/j.bbmt.2018.04.004>

Reference: YBBMT 55088


To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 2-4-2018

Accepted date: 5-4-2018

Please cite this article as: Christopher G. Kanakry, Leo Luznik, Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform, *Biology of Blood and Marrow Transplantation* (2018), <https://doi.org/10.1016/j.bbmt.2018.04.004>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title: Teaching a young dog new tricks: Modifications to the post-transplantation cyclophosphamide haploidentical transplantation platform

Authors: Christopher G. Kanakry¹ and Leo Luznik²

Affiliations: ¹Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; ²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

Correspondence: Christopher G. Kanakry, MD, 10 Center Drive, Building 10-CRC, Room 4-3142, Bethesda, Maryland 20892, Tel: 301-435-5280, Fax: 301-451-5667, Email: christopher.kanakry@nih.gov

Disclosures: The authors have no relevant disclosures or conflicts of interest.

In this manuscript, Chiusolo and colleagues report retrospective outcomes of 150 patients with acute myeloid leukemia transplanted with a human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (HCT) platform using post-transplantation cyclophosphamide (PTCy).¹ This platform was adapted from the Johns Hopkins (Baltimore) regimen² with the major modifications being the incorporation of myeloablative conditioning and the timing of the immunosuppression. The changes to the immunosuppression included starting cyclosporine (CsA) on day 0 and mycophenolate mofetil (MMF) on day +1 and spacing the days of PTCy from +3 and +4 to +3 and +5. Despite these alterations, GVHD and overall transplant outcomes were excellent. The cumulative incidence of grade III-IV acute GVHD of 5% was identical with that found using the Johns Hopkins regimen, and the incidence of grade II-IV acute GVHD was actually lower (17% versus 30%).³ The incidence of

Download English Version:

<https://daneshyari.com/en/article/8429805>

Download Persian Version:

<https://daneshyari.com/article/8429805>

[Daneshyari.com](https://daneshyari.com)